Sort   by:  
 Page size 
TranscriptomicsExpression profiling of BRAFV600E melanoma cell lines upon RAF inhibition
Microarray expression analysis to identify global changes in transcription in response to RAF inhibition. Genes under RAF control were identified in a panel of BRAFV600E tumor cells, following the short-term inhibition of RAF using a pan-RAF kinase inhibitor, PLX4032 (Plexxikon). For comparison with...
ORGANISM(S): Homo sapiens 
2010-07-18 | E-GEOD-20051 | biostudies-arrayexpress
TranscriptomicsExpression data from melanoma cell lines
Differential gene expression analysis of parental and resistant sub-lines of melanoma cell lines treated or untreated with PLX4032 Using microarray we sought to obtain a genome-wide profile of differentially expressed genes in parental melanoma cell lines and resistant sub-lines in response to PLX40...
ORGANISM(S): Homo sapiens 
2010-11-26 | E-GEOD-24862 | biostudies-arrayexpress
GenomicsTranscriptomic Analysis of Control and PLX4032 Resistant Clones with RNA Sequencing
Transcriptomic Analysis of Control and PLX4032 Resistant Clones with RNA Sequencing
PRJNA565142 | ENA
GenomicsEpigenome analysis of Control and PLX4032 Resistant Clones with EPIC array.
Epigenome analysis of Control and PLX4032 Resistant Clones with EPIC array.
PRJNA565587 | ENA
TranscriptomicsCOLO829 treatment with PLX4032 and/or MITF knockdown
Thousands of enhancers are characterized in the human genome, yet few have been shown important in cancer. Inhibiting oncokinases, such as EGFR, ALK, HER2, and BRAF, is a mainstay of current cancer therapy but is hindered by innate drug resistance mediated by upregulation of the HGF receptor, MET. T...
ORGANISM(S): Homo sapiens 
2014-01-14 | E-GEOD-50649 | biostudies-arrayexpress
GenomicsAnalysis of resistance to PLX4032
We have collected material from a patient who had BrafV600E mutant melanoma that was treated with PLX4032. We have germline DNA from the patient and DNA and RNA from distinct lesions before and after treatment with PLX4032. We would like to exome sequence these samples to gain a snap shot of the mec...
EGAS00001000415 | EGA
GenomicsThe Transcriptome of PLX4032 resistance
We have collected material from a patient who had BrafV600E mutant melanoma that was treated with PLX4032. We have germline DNA from the patient and DNA and RNA from distinct lesions before and after treatment with PLX4032. We have transcriptome sequenced these samples to obtain a snap shot of the m...
EGAS00001000413 | EGA
UnknownVitamin C sensitizes BRAFV600E thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032.
Not available
S-EPMC7816401 | biostudies-literature
TranscriptomicsThe Transcriptome of PLX4032 resistance
We have collected material from a patient who had BrafV600E mutant melanoma that was treated with PLX4032. We have germline DNA from the patient and DNA and RNA from distinct lesions before and after treatment with PLX4032. We have transcriptome sequenced these samples to obtain a snap shot of the m...
ORGANISM(S): Homo sapiens 
2013-06-07 | E-ERAD-138 | biostudies-arrayexpress
GenomicsCharacterization of human BRAF mutated melanoma cells that persist after PLX4032 treatment
Characterization of human BRAF mutated melanoma cells that persist after PLX4032 treatment
PRJNA523849 | ENA
Sort   by:  
 Page size